Results 51 to 60 of about 19,767 (298)

Management of Dopamine Agonist-Resistant Prolactinoma

open access: yesNeuroendocrinology, 2019
Dopamine agonists are usually very effective in the treatment of prolactinomas. Nonetheless, a subset of individuals does not respond satisfactorily to these agents, and this resistance is characterized by failure to achieve normoprolactinemia and a 30 ...
D. Maiter
semanticscholar   +1 more source

Anti-c-myc efficacy block EGFL7 induced prolactinoma tumorigenesis

open access: yesOpen Chemistry, 2019
Resistance to Dopamine agonists therapy is still a key factor that hinders the clinical treatment of prolactinoma. Consequently, a large number of investigations have been carried out to identify novel therapeutic targets.
Lan Xiaolei   +4 more
doaj   +1 more source

Advances in the treatment of prolactinomas [PDF]

open access: yes, 2006
Prolactinomas account for approximately 40% of all pituitary adenomas and are an important cause of hypogonadism and infertility. The ultimate goal of therapy for prolactinomas is restoration or achievement of eugonadism through the normalization of ...
1997 Data on file   +627 more
core   +1 more source

Increased Lipid Levels Improves after Treatment with Cabergolin in Patients with Prolactinoma

open access: yesMedicine Science, 2015
It has been suggested that hyperprolactinemia may be associated with obesity and dyslipidemia. However it is not fully understood that dyslipidemia is occurs independently or due to obesity.
Mazhar Muslum Tuna   +5 more
doaj   +1 more source

Late presentation of acromegaly in medically controlled prolactinoma patients

open access: yesEndocrinology, Diabetes & Metabolism Case Reports, 2016
Co-secretion of growth hormone (GH) and prolactin (PRL) from a single pituitary adenoma is common. In fact, up to 25% of patients with acromegaly may have PRL co-secretion.
Ekaterina Manuylova   +6 more
doaj   +1 more source

Quality of life in Prolactinoma: A systematic review

open access: yesPituitary
Prolactinomas are common tumours that significantly reduce quality-of-life (QOL) due to sellar mass effect, secondary hypogonadism, and the peripheral effects of prolactin.
Mendel Castle-Kirszbaum   +3 more
semanticscholar   +1 more source

Giant Prolactinoma Causing Hydrocephalus and Intracranial Hypertension as First Manifestations of Multiple Endocrine Neoplasia Type 1

open access: yesFrontiers in Endocrinology, 2019
Context: Overall, giant prolactinomas are rare tumors (4%), especially those larger than 60 mm (1%). Despite the predominance of macroadenoma documented in multiple endocrine neoplasia type 1 (MEN1)-related prolactinoma, only three giant prolactinoma ...
Naiara C. B. Dantas   +6 more
doaj   +1 more source

Dissociation between the effects of somatostatin (SS) and octapeptide SS-analogs on hormone release in a small subgroup of pituitary- and islet cell tumors [PDF]

open access: yes, 1997
The effects of somatostatin (SS-14 and/or SS-28) and of the three octapeptide SS-analogs that are available for clinical use (octreotide, BIM-23014 and RC-160) on hormone release by primary cultures of 15 clinically ...
Herder, W.W. (Wouter) de   +9 more
core   +3 more sources

Predictors of the Response to Dopaminergic Therapy in Patients with Prolactinoma.

open access: yesJournal of Clinical Endocrinology and Metabolism, 2020
PURPOSE Withdrawal of dopamine agonist (DA) therapy in patients with prolactinoma who are controlled by a small dose of medication is recommended by several guidelines.
Camille Hage, R. Salvatori
semanticscholar   +1 more source

Identification of potential and novel target genes in pituitary prolactinoma by bioinformatics analysis

open access: yesAIMS Neuroscience, 2021
Pituitary prolactinoma is one of the most complicated and fatally pathogenic pituitary adenomas. Therefore, there is an urgent need to improve our understanding of the underlying molecular mechanism that drives the initiation, progression, and metastasis
Vikrant Ghatnatti   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy